Scholarlink

Coronavirus disease (COVID-19) has been caused by the recent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) outbreak, which has had a global impact on public health. Researchers are diligently striving despite numerous obstacles to develop an efficacious treatment for COVID-19, given the absence of a well-established therapeutic approach. Limited empirical treatment protocols were substantiated by scientific evidence from previous viral epidemics of a similar nature. An investigation into therapeutic approaches, such as the repurposing of pre-existing antiviral agents, has become imperative in light of the COVID-19 pandemic. This chapter provides an analysis of the potential of repurposed pharmaceuticals to combat SARS-CoV-2, with a specific emphasis on their efficacy, safety profiles, and mechanisms of action. Remdesivir, an RNA polymerase inhibitor initially designed for the treatment of the Ebola virus, and favipiravir, a broad-spectrum antiviral utilised against influenza, are among the agents under discussion. Furthermore, this chapter provides an in-depth analysis of the repurposing capabilities of pharmaceuticals such as lopinavir/ritonavir and hydroxychloroquine, illuminating the contentious issues that encircle their safety and efficacy in the management of COVID-19. Novel methods including protease inhibitors like Camostat mesylate and molnupiravir, an oral antiviral that promotes deadly RNA mutagenesis, are being investigated to reduce viral proliferation and illness severity. Researchers and medical professionals have been investigating innovative medication prophylaxis and therapy using drug repurposing techniques. Thus, novel and effective medications that may provide a fresh perspective on the management of the current SARS-CoV-2 pandemic have become a critical need. By conducting an extensive examination of these repurposed agents, the objective of this chapter is to offer valuable perspectives on their therapeutic efficacy, obstacles, and potential future developments in the fight against COVID-19.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Repurposing of Antiviral Agents in COVID-19

  • 章节

  • 发表日期：

    2025年

查看全文
  • Shailendra Dwivedi,
  • Vijay Singh,
  • Akash Bansal,
  • Radhieka Misra,
  • Alka Tripathi,
  • Sanjeev Misra

摘要

Coronavirus disease (COVID-19) has been caused by the recent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) outbreak, which has had a global impact on public health. Researchers are diligently striving despite numerous obstacles to develop an efficacious treatment for COVID-19, given the absence of a well-established therapeutic approach. Limited empirical treatment protocols were substantiated by scientific evidence from previous viral epidemics of a similar nature. An investigation into therapeutic approaches, such as the repurposing of pre-existing antiviral agents, has become imperative in light of the COVID-19 pandemic. This chapter provides an analysis of the potential of repurposed pharmaceuticals to combat SARS-CoV-2, with a specific emphasis on their efficacy, safety profiles, and mechanisms of action. Remdesivir, an RNA polymerase inhibitor initially designed for the treatment of the Ebola virus, and favipiravir, a broad-spectrum antiviral utilised against influenza, are among the agents under discussion. Furthermore, this chapter provides an in-depth analysis of the repurposing capabilities of pharmaceuticals such as lopinavir/ritonavir and hydroxychloroquine, illuminating the contentious issues that encircle their safety and efficacy in the management of COVID-19. Novel methods including protease inhibitors like Camostat mesylate and molnupiravir, an oral antiviral that promotes deadly RNA mutagenesis, are being investigated to reduce viral proliferation and illness severity. Researchers and medical professionals have been investigating innovative medication prophylaxis and therapy using drug repurposing techniques. Thus, novel and effective medications that may provide a fresh perspective on the management of the current SARS-CoV-2 pandemic have become a critical need. By conducting an extensive examination of these repurposed agents, the objective of this chapter is to offer valuable perspectives on their therapeutic efficacy, obstacles, and potential future developments in the fight against COVID-19.